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Vitamin D exists in several forms comprising steroid-
like fat-soluble molecules (secosteroids).1, Cholecalciferol 
(vitamin D3) is synthesized in the skin in response to 
solar ultraviolet radiation B producing photochemical 
cleavage of a cholesterol precursor (7-dehydro-
cholesterol).1-3 Irradiation of ergosterol, a membrane 
sterol found in the Ergot fungus, produces ergocalciferol 
(vitamin D2). Dietary sources of vitamin D include fish 
oils (D3), egg yolk (D3), mushrooms (D2), and fortified 
cereals and dairy products (D2 or D3). Vitamin D derived 
from all different sources undergoes two successive 
hydroxylation steps, first in the liver (25-hydroxyvitamin 
D / calcidiol) and then the kidney (1, 25-hydroxyvitamin 
D2 / calcitriol). The former form has a longer half-life 
than the latter (weeks vs. several hours). The biologic 
effects of vitamin D result largely from its binding to the 
vitamin D receptor (VDR), a nuclear steroid hormone 
found in almost every tissue. Calcitriol (D2), the active 
compound, appears to have the greatest affinity for the 
receptor. As the VDR is expressed on cardiac myocytes, 
one can expect direct actions of vitamin D in the heart. In 
addition, there is a VDR-mediated suppressive effect of 
the vitamin D upon the renin-angiotensin-system (RAS).2  
 
The prevalence of vitamin D deficiency is estimated 
around 20–50% in the adult population in developed 
countries, mostly the result of insufficient cutaneous 
production due to decreased exposure to sunlight, and to a 
less degree from low dietary intake.4 A higher prevalence 
(74%) has been reported in patients with CVD, 
particularly in those with coronary heart disease and heart 
failure.Kim The serum level of 25-hydroxyvitamin D best 
represents overall vitamin D status as this measurement 
reflects total vitamin D from dietary intake and sunlight 
exposure, as well as the conversion of vitamin D from 
adipose stores in the liver.3 Serum levels of 25-
hydroxyvitamin D >30 ng/mL are considered adequate, 
while levels < 20 ng/mL are diagnostic of vitamin D 
deficiency.  
The endocrine functions of vitamin D in relation to 
bone metabolism and mineral ion homoeostasis are well 
known.3 Vitamin D deficiency results in reduced 
intestinal absorption of calcium, which stimulates the 
production of parathyroid hormone with an ensuing 
accelerated bone de-mineralization to maintain serum 
calcium concentration, with all these alterations leading 
to the clinical effects of hypocalcemia. These may rarely 
result in tetany, but due to gradual and insidious 
development, more commonly produce local, or diffuse 
musculo-skeletal aches and pains.  
Importantly, more recent epidemiological studies have 
linked vitamin D deficiency with the pathogenesis of 
cardiovascular disease (CVD) and an attendant increase 
in cardiovascular morbidity and mortality, but data for a 
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causal relationship are still missing.1,6,7 Experimental 
studies have proposed novel actions of vitamin D 
metabolites on cardiac myocytes, as well as on 
endothelial and vascular smooth muscle cells. Low levels 
of 25-hydroxyvitamin D are associated with left 
ventricular hypertrophy, vascular dysfunction, and 
activation of the renin–angiotensin system.2,8,9 However, 
the cardiovascular benefits of vitamin D supplementation 
in those without renal disease or hyperparathyroidism 
have not been demonstrated.10,11 Thus, important 
questions remain about the real role of vitamin D 
deficiency as a cardiovascular risk rather than mere 
reflection of a classic risk burden.  
 
Nevertheless, the evidence is growing suggesting that 
vitamin D may play an important role in cardiovascular 
health status. Vitamin D receptor (VDR) and enzymes for 
vitamin D metabolism are expressed in both heart and 
vessels. Many observational studies have suggested that 
vitamin D deficiency may be associated with CVD and its 
risk factors. Low vitamin concentrations are an 
independent risk factor for cardiovascular events, 
including myocardial infarction, strokes and all-cause, 
cardiac and sudden deaths.1, 6, 12, 13 An association of VDR 
gene variants with CAD risk has been suggested in a 
prospective cohort of type II diabetic patients.14 Some trials 
with pure vitamin D supplementation have indicated 
beneficial effects on cardiovascular risk factors such as 
arterial hypertension.15,16  
 
According with the Nova Scotia Health Survey, 17 
among 244 patients with prior cardiovascular disease 
(ischemic heart disease, peripheral vascular disease, or 
stroke), marked vitamin D deficiency (levels of <15 
ng/mL) was associated with an increased risk of ischemic 
events over a 10-year follow-up period. A total of 114 
ischemic events occurred during the 10-year follow-up. 
Vitamin D levels of <30 ng/mL were associated with a 
hazard ratio of 1.33 (p=0.172) for ischemic events 
compared to levels ≥30 ng/mL, but levels of <15 ng/mL 
were associated with a hazard ratio of 2.30 (p=0.035) for 
ischemic events compared to levels ≥30 ng/mL.  
 
In a Danish study, plasma 25-hydroxyvitamin D levels 
were measured in 10,170 people not receiving vitamin D-
fortified food.2 Over 29 years, 6747 died, 3100 
individuals developed ischemic heart disease (IHD), and 
1625 suffered an acute myocardial infarction (MI). 
Increasing risk of IHD, MI, and early death was 
correlated with decreasing plasma 25-hydroxyvitamin D 
levels. Multivariate analysis indicated that individuals 
with plasma 25-hydroxyvitamin D levels at the 1st to 4th 
percentile compared with individuals with levels at the 
50th to 100th percentile, had an adjusted risk increased by 
40% for IHD, by 64% for MI, by 57% for early death, (or 
81% for combined fatal IHD/MI). In the meta-analyses of 
18 and 17 studies, risk of IHD and early death were 
increased by 39% and 46% for lowest vs highest quartile 
of 25-hydroxyvitamin D level. The authors concluded 
that with decreasing levels of vitamin D an increasing 
risk of IHD, MI, and early death was noted, findings 
which were corroborated in the meta-analyses.2  
An analysis of the third National Health and Nutrition 
Examination Survey (1988–1994) (NHANES III) 
examined the association between serum 25-
hyrdoxyvitamin D levels and 8% prevalence of CVD 
(angina, myocardial infarction or stroke) in 16,603 men 
and women aged >18 years.18 Participants with CVD had 
a greater frequency of 25-hyrdoxyvitamin D deficiency 
(<20 ng/mL) than those without (29.3% vs. 21.4%; p < 
0.0001). Multivariate analysis indicated that participants 
with 25-hyrdoxyvitamin D deficiency had an increased 
risk of prevalent CVD (odds ratio 1.20; p = 0.03). 
Mechanisms by which vitamin D deficiency may 
confer increased cardiovascular risk include the 
development of electrolyte imbalances, pancreatic β-cell 
dysfunction, and RAS activation.19 In addition, disrupted 
adaptive immune responses with severe vitamin D 
deficiency result in an inflammatory milieu that promotes 
vascular dysfunction and insulin resistance. Indeed, most 
epidemiological studies have reported an inverse 
relationship between vitamin D status and the prevalence 
of established cardiovascular risk factors such as age, 
hypertension, diabetes, and hypertriglyceridemia. Serum 
25-OH D levels are also lower in women, in obesity, and 
in those with decreased physical activity. A recent study 
of 554 subjects indicated that vitamin D insufficiency was 
associated with increased arterial stiffness and endothelial 
dysfunction in the conductance and resistance blood 
vessels, independent of the presence or absence of 
traditional risk factors.20 Furthermore, normalization of 
vitamin D status in insufficient individuals was associated 
with improvement in vascular function. 
The association between vitamin D deficiency and 
hypertension perhaps offers the most convincing 
evidence for the involvement of vitamin D metabolism in 
the pathogenesis of cardiovascular disease.16,21,22 Current 
evidence indicates that vitamin D deficiency may 
promote vascular dysfunction and sustained RAS 
activation.9,20,23,24 Among other studies, the third National 
Health and Nutrition Examination (NHANES III) looked 
at serum 25-OH D in relation to CVD risk factors in over 
13 000 US adults. 22 After multivariable adjustment, those 
with 25-OHD levels in the lowest quartile had a 
significantly higher prevalence of hypertension compared 
with those in the highest quartile, and sufficient levels 
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attenuated the expected age-related increases in blood 
pressure. In addition to its relation to hypertension (odds 
ratio-OR, 1.30), vitamin D deficiency was also associated 
with higher prevalence of diabetes mellitus (OR, 1.98), 
obesity (OR, 2.29), and high serum triglyceride levels 
(OR, 1.47) (P<0.001).22 Furthermore, hypovitaminosis D 
appears to be highly prevalent in various CVDs, such as 
coronary artery disease, heart failure, stroke and 
peripheral arterial disease.5   
 
With regards to the association of vitamin D 
deficiency with diabetes mellitus, experimental data 
indicate an effect on insulin synthesis, secretion, and 
sensitivity by modulating pancreatic RAS activity and 
regulating calcium ion traffic across β-cells. In addition, 
vitamin D deficiency may produce abnormal immune 
responses that precipitate an inflammatory reaction and 
subsequent insulin resistance. Several studies indicate a 
higher incidence and prevalence of type I diabetes 
mellitus with depressed vitamin D status, as well as an 
association with insulin resistance, obesity, glucose 
intolerance, and type II diabetes.25 Other potential 
consequences of vitamin D deficiency may include an 
exacerbation of atherogenesis and acceleration of arterial 
calcification. Experimental studies show that vitamin D 
deficiency may produce endothelial cell dysfunction, 
while vitamin D supplementation may improve 
endothelial function in diabetic patients.26 
Vitamin D deficiency is also most prevalent in heart 
failure patients, culminating to 80-95% 27 and may be 
ascribed to nutritional deficiency, decreased skin 
production, reduced intestinal absorption, and hepatorenal 
disease.28 Hypovitaminosis D has been linked with poor 
clinical outcomes with increased morbidity and mortality 
in this patient population.29 However, it is not clear which 
is the pathophysiological mechanism involved. It has 
been suggested that the renin–angiotensin–aldosterone 
system and pro-inflammatory cytokines may possibly be 
involved in mediating a poor outcome via the cardiorenal 
syndrome. Data with regards to the benefit of vitamin D 
supplementation in ameliorating this relationship remain 
scanty.30 Nevertheless, vitamin D may constitute a new 
therapeutic target in patients with heart failure. Further 
studies are needed to better clarify the pathogenetic 
mechanisms and also to further investigate the role of 
vitamin D monitoring and supplementation in these 
patients. 
A meta-analysis of 18 randomized controlled trials 
comprising over 57000 patients indicated that oral 
supplementation of vitamin D (most daily doses at 400-
800 IU) was associated with a 7% reduction of total 
mortality.11 The authors postulated that various protective 
mechanisms of vitamin D might have contributed to this 
benefit. Among them, its pleiotropic skeletal and 
extraskeletal effects on calcium homeostasis, bone 
formation, cellular proliferation and differentiation, 
immune system, rennin production, endothelial function 
and vascular protection. They also point to effects 
mediated through the activation of the vitamin D 
receptor, such as inhibition of cellular proliferation and 
activation of cellular differentiation, which could reduce 
aggressiveness of cancerous processes and expansion of 
atheromatous lesions.11 However, another meta-analysis 
of 51 trials indicated a non-significant 4% reduction of 
cardiovascular mortality conferred by vitamin D.7 No 
effect was observed on myocardial infarction or stroke. 
There is a concern that the addition of calcium in the 
supplement regimen may be detrimental, although this 
remains a controversial issue.2,31,32  
Finally, whether vitamin D deficiency is directly 
related to CVD or its effect on most CVD risk factors 
leads to an increased cardiovascular morbidity and 
mortality remains a moot point. Nevertheless, in either 
case, further randomized trials are needed to elucidate 
whether vitamin D supplementation will ameliorate these 
adverse effects of vitamin D deficiency and provide 
cardiovascular protection.2,10 Such ongoing trials, the 
VITAL and ViDA trials, will examine, in 20,000 (>60 
years) and 5000 patients (50-84 years) respectively, the 
effects of vitamin D (either 2000 IU daily alone or in 
combination with omega-3 fatty acids; or 100000 IU 
monthly, respectively) on developing heart disease, stroke 
or cancer; or heart or respiratory disease or fractures, 
respectively.33 Another trial, whereby patients with CVD 
will be given either 150,000 IU of vitamin D3 every two 
months or placebo over one year, will assess the 
association between rise in calcidiol level and incidence 
of new cardiovascular events.2  
  
REFERENCES  
 
1. McGreevy, Williams D. New insights about vitamin D and 
cardiovascular disease. Ann Intern Med. 2011;155:820-826.  
2. Brandenburg VM, Vervloet MG, Marx N. The role of 
vitamin D in cardiovascular disease: From present evidence 
to future perspectives. Atherosclerosis 2012;225: 253-263.  
3. Rosen CJ. Vitamin D insufficiency. N Engl J Med 
2011;364:248-254.  
4. Zadshir A, Tareen N, Pan D, Norris K, Martins D. The 
prevalence of hypovitaminosis D among US adults: data 
from the NHANES III. Ethn Dis 2005;15(suppl 5):S5–
S101. 
5. Kim DH, Sabour S, Sagar UN, Adams S, Whellan DJ.  
Prevalence of hypovitaminosis D in cardiovascular diseases 
(from the National Health and Nutrition Examination 
Survey 2001 to 2004). Am J Cardiol 2008;102:1540 –1544.  
24 
 
6. Dobnig H, Pilz S, Scharnagl H, et al. Independent 
association of low serum 25-hydroxyvitamin D and 1,25-
dihydroxyvitamin D levels with all-cause and 
cardiovascular mortality. Arch Intern Med 2008; 168: 
1340–1349. 
7. Elamin MB, Abu Elnour NO, Elamin KB, et al. Vitamin D 
and cardiovascular outcomes: a systematic review and 
meta-analysis. J Clin Endocrinol Metab 2011;96:1931-
1942. 
8. Li YC, Kong J,Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-
Dihydroxyvitamin D(3) is a negative endocrine regulator of 
the renin-angiotensin system. J Clin Invest 2002; 110:229–
238.  
9. Vaidya A, Williams JS. The relationship between vitamin D 
and the renin-angiotensin system in the pathophysiology of 
hypertension, kidney disease, and diabetes. Metabolism 
2012;61:450–458. 
10. Wang L, Manson JE, Song Y, Sesso HD. Systematic 
review: vitamin D and calcium supplementation in 
prevention of cardiovascular events. Ann Intern Med 2010; 
152:315–323. 
11. Autier P, Gandini S. Vitamin D supplementation and total 
mortality. A meta-analysis of randomized controlled Trials. 
Arch Intern Med 2007;167:1730-1737.  
12. Giovannucci E, Liu Y, Hollis BW, Rimm EB. 25-
Hydroxyvitamin D and risk of myocardial infarction in 
men. A prospective study. Arch Intern Med 2008;168:1174-
1180.  
13. Brøndum-Jacobsen P, Ben n M, Jensen GB, Nordestgaard 
BG. 25-Hydroxyvitamin D levels and risk of ischemic heart 
disease, myocardial Infarction, and early death. Population-
based study and meta-analyses of 18 and 17 studies. 
Arterioscler Thromb Vasc Biol 2012; 32: 2794-2802.  
14. Ferrarezi DA, Bellili-Muñoz N, Dubois-Laforgue D, et al. 
Allelic variations of the vitamin D receptor (VDR) gene are 
associated with increased risk of coronary artery disease in 
type 2 diabetics: The DIABHYCAR prospective study. 
Diabetes Metab 2013; doi: 10.1016/j.diabet.2012.11.004. 
Epub 2013 Jan 23. 
15. Witham MD, Nadir MA, Struthers AD. Effect of vitamin on 
blood pressure: a systematic review and meta-analysis. J 
Hypertens 2009;27:1948–1954. 
16. Pilz S, Tomaschitz A, Ritz E, Pieber TR. Vitamin D status 
and arterial hypertension: a systematic review. Nature Rev 
2009;6:621–630. 
17. Wasson LT, Shimbo D, Rubin MR, Shaffer JA, Schwartz 
JE, Davidson KW. Is vitamin D deficiency a risk factor for 
ischemic heart disease in patients with established 
cardiovascular disease? 10-year follow-up of the Nova 
Scotia Health Survey. Int J Cardiol 2011;148: 387-389.  
18. Kendrick J, Targher G, Smits G, Chonchol M. 25 
hydroxyvitamin D deficiency is independently associated 
with cardiovascular disease in the Third National Health 
and Nutrition Examination Survey. Atherosclerosis 
2009;205: 255–260.  
19. Motiwala SR, Wang TJ. Vitamin D and cardiovascular risk. 
Curr Hypertens Rep 2012; 14:209–218.  
20. Al Mheid I, Patel R, Jonathan Murrow J, et al. Vitamin D 
status is associated with arterial stiffness and vascular 
dysfunction in healthy humans. J Am Coll Cardiol 
2011;58:186–192. 
21. Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25-
hydroxyvitamin D levels and risk of incident hypertension. 
Hypertension 2007;49:1063–1069. 
22. Martins D, Wolf M, Pan D, et al. Prevalence of 
cardiovascular risk factors and the serum levels of 25-
hydroxyvitamin D in the United States. Data from the Third 
National Health and Nutrition Examination Survey. Arch 
Intern Med 2007;167:1159-1165.  
23. Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D 
deficiency and replacement on endothelial function in 
asymptomatic subjects. J Clin Endocrinol Metab 2009;94: 
4023–4030. 
24. Zagura M, Serg M, Kampus P, et al. Aortic stiffness and 
vitamin D are independent markers of aortic calcification in 
patients with peripheral arterial disease and in healthy 
subjects. Eur J Vasc Endovasc Surg 2011;42:689–695. 
25. Boucher BJ, John WG, Noonan K. Hypovitaminosis D is 
associated with insulin resistance and beta cell dysfunction. 
Am J Clin Nutr 2004;80:1666. author reply 1666–1667. 
26. Sugden JA, Davies JI, Witham MD, Morris AD, Struthers 
AD. Vitamin D improves endothelial function in patients 
with type 2 diabetes mellitus and low vitamin D levels. 
Diabet Med 2008;25:320–325. 
27. Agarwal M, Phan A, Willix R Jr, Barber M, Schwarz ER. Is 
vitamin D deficiency associated with heart failure? A 
review of current evidence. J Cardiovasc Pharmacol Ther 
2011;16:354-363.  
28. Patel R, Rizvi AA. Vitamin D deficiency in patients with 
congestive heart failure: mechanisms, manifestations, and 
management. South Med J 2011;104:325-330.  
29. Pourdjabbar A, Dwivedi G, Haddad H. The role of vitamin 
D in chronic heart failure. Curr Opin Cardiol 2013;28:216-
222. 
30. Amin A, Minaee S, Chitsazan M, Naderi N, Taghavi S, 
Ardeshiri M. Can vitamin D supplementation improve the 
severity of congestive heart failure? Congest Heart Fail 
2013 Mar 21. doi: 10.1111/chf.12026. [Epub ahead of print] 
31. Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D 
supplementation and cardiovascular events. Circulation 
2007;115:846-854. 
32. Xiao Q, Murphy RA, Houston DK, Harris TB, Chow W-H, 
Park Y. Dietary and supplemental calcium intake and 
cardiovascular disease mortality. The National Institutes of 
Health–AARP Diet and Health Study. JAMA Intern Med 
2013; Feb 4, 2013. doi:10.1001/jamainternmed.2013.3283.  
33. Camargo CA. Vitamin D and cardiovascular disease. Time 
for large randomized trials. J Am Coll Cardiol 2011; 
58:1442–1444.  
